Authors
Latest:
Dr. Kochenderfer Discusses the B-cell Antigen CD19Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19
Latest:
The Aggressive Peripheral T-Cell LymphomasThe aggressive peripheral T-cell lymphomas make up less than 10% of all lymphomas diagnosed each year in the United States.
Latest:
Dr. Allison on the Urgency of Drug Development in OncologyJames P. Allison, PhD, discusses his experience with the urgency of drug development in oncology.
Latest:
Maintenance Strategies After Initial Chemotherapy for Non-Small Cell Lung CancerJames P. Stevenson, MD, discusses optimization of drug and patient selection for maintenance therapies in NSCLC, and how it will continue to be a research focus in today's environment of value-based care.
Latest:
Dr. Berenson Discusses Results from the CHAMPION-1 TrialJames R. Berenson, MD, founder, President and Medical and Scientific Director of the Institute for Myeloma and Bone Cancer Research, President of Oncotherapeutics, discusses the dose-escalation portion of the phase I/II CHAMPION-1 study looking at weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Jett on Debates on Molecular Testing for Lung CancerJames R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.
Latest:
Managing Oral Mucositis in Patients With CancerOne of the most uncomfortable consequences of anticancer therapy is the development of oral mucositis.
Latest:
Dr. Mark on the Use of Degarelix in Men With Prostate CancerJames Ryan Mark, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the use of degarelix (Firmagon) in the treatment of men with prostate cancer.
Latest:
Advanced Squamous Carcinoma of the Skin: A Persistent, Growing ChallengeAdvanced SCCS continues to be a treatment challenge given the aggressive behavior of a subset of cases and the absence of randomized clinical trials to provide guidelines for therapy.
Latest:
Dr. Stevenson on the Importance of Early Screening in Lung CancerJames Stevenson, MD, discusses the importance of early screening in lung cancer.
Latest:
Dr. Thigpen on Ovarian Cancer Drugs Not Approved by FDAJames "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses the use of agents in ovarian cancer that are not approved by the FDA.
Latest:
Dr. Urbanic on the Evolution of Radiation in NSCLCJames Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.
Latest:
Dr. James Fleshman on Minimally Invasive Surgery for Colorectal CancerJames W. Fleshman Jr, MD, from the Department of Surgery and Internal Medicine at Baylor University Medical Center, discusses the surgical management of colorectal cancer.
Latest:
Dr. Weitzman on Sequencing Challenges in Myeloma TreatmentJames Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.
Latest:
Dr. Welsh on New Understanding of Regulating PD-L1 ExpressionJames Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.
Latest:
Dr. Wysock on the Role of Cytoreductive Nephrectomy in RCCJames Wysock, MD, chief of the urology service at NYC Health and Hospitals at Bellevue, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses the role of cytoreductive nephrectomy in renal cell carcinoma.
Latest:
Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLCJames Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.
Latest:
Circling the Latest With ctDNA in Lung CancerJoshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.
Latest:
Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic MalignanciesJamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.
Latest:
Jamie Myers Describes the Design of Her CRCI StudyJamie Myers Describes the Design of Her Chemotherapy-Related Cognitive Impairment Study
Latest:
The Future of Myeloproliferative Neoplasm TreatmentThe panelists conclude their discussion by highlighting investigational agents to look forward to.
Latest:
Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and ShammoOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
